When was Medpace founded?
Medpace, Inc. was officially founded in Cincinnati, Ohio, in 1992 by Dr. August Troendle, a former medical officer for the Food and Drug Administration. The enterprise was established as a scientifically driven, full-service clinical contract research organization designed to partner with pharmaceutical and biotechnology companies to accelerate the clinical development of novel drugs and medical devices. Over more than three decades, Medpace expanded its global operations across numerous countries, providing comprehensive clinical trial management services.
Related FAQs
Medpace operates strictly as a scientifically driven, full-service contract research organization (CRO) providing comprehensive global clinical development support to pharmaceutical, biotechnology, and medical device companies.
The Tobacco Master Settlement Agreement of 1998 stands as the largest and most expensive civil lawsuit settlement in United States history, totaling an astonishing $206 billion.
Medpace operates strictly as a contract research organization (CRO) rather than a drug development sponsor.
Medpace is widely categorized by institutional investors and equity analysts as a classic growth stock, characterized by robust double-digit historical revenue expansion, rapidly scaling earnings, and high reinvestment rates into its core clinical re...
Wall Street equity analysts frequently assign favorable ratings to Medpace, with consensus opinions often landing between a moderate buy and a strong buy based on its stellar operating margins and superior backlog conversion rates compared to industr...
Medpace offers a hybrid work model for various corporate, administrative, and data management positions, but many of its clinical operations, laboratory roles, and project management functions require regular on-site presence at its corporate campus ...
The Medpace stock lawsuit refers to a securities class action lawsuit filed against Medpace Holdings Inc. and certain executive officers on behalf of investors who acquired common stock.
Medpace operates as a scientifically-driven clinical contract research organization providing comprehensive, phase-specific development services for pharmaceutical, biotechnology, and medical device enterprises.
Life at Medpace is defined by a culture of collaboration, expertise, and high expectations. Employees work within a mission-driven environment focused on accelerating the development of safe medical therapeutics.
As of the most recent market data from July 24, 2026, the stock price for China Mengniu Dairy Company Ltd, which trades under the symbol 2319 on the Hong Kong Stock Exchange, was 18.10 Hong Kong dollars per share.
Medpace is a genuine, highly established corporate entity operating globally within the life sciences and clinical research sector.
Medpace is fundamentally an American corporation, maintaining its corporate headquarters and primary integrated clinical research campus in Cincinnati, Ohio.
Medpace, a prominent clinical contract research organization supporting global biopharmaceutical and medical device enterprises, provides competitive compensation packages for its clinical research associates, biostatisticians, project managers, and ...
Medpace Holdings, Inc.
Compensation for merchant bankers and corporate financial advisors varies extensively depending on transaction deal flow, firm size, geographic market, and performance-based commission structures.
Medpace Holdings is an entirely legitimate, publicly traded multinational clinical research organization listed on the NASDAQ exchange under the ticker symbol MEDP and recognized as a component of the S&P mid-cap index.
Equity research analysts tracking Medpace Holdings (trading under the ticker MEDP) generally evaluate the stock as an attractive growth investment, though opinions fluctuate based on broader biotechnology funding cycles and valuation multiples.